Main Logo
SGLT2 inhibitors

DocWire News EditorsCardiology | May 13, 2022
Coronary Heart Disease Risk Factors and Serum Expression Analysis ...
Read More
Amit Goyal, MDCardioNerds | May 10, 2021
Editor's Note: This content was written by Amit Goyal, MD, a cardiology fellow at the Cleveland Clinic, and co-founder ...
DocWire News EditorsHeart Failure | May 2, 2023
The manufacturers of Jardiance (empagliflozin) accounted that the FDA has granted FastTrack status to the drug for the ...
DocWire News EditorsHeart Failure | May 2, 2023
Dapagliflozin appears safe and effective across different diuretic subgroups of heart failure patients, a new analysis ...
DocWire News EditorsCardiology | September 14, 2023
This week's edition features some drug updates: one on SGLT-2 inhibitors in type 2 diabetic patients, and another on ...
DocWire News EditorsCardiology | September 14, 2023
The 2019 Heart Failure Society of America Scientific Meeting (HFSA 2019) in Philadelphia has wrapped up. DocWire News ...
DocWire News EditorsCardiology | April 19, 2019
This week's edition includes some troubling findings for statins, good things happening with canagliflozin, a new add-on ...
DocWire News EditorsCardiology | April 11, 2023
Semaglutide (OZEMPIC) taken weekly as an add-on therapy to sodium-glucose cotransporter-2 (SGLT-2) inhibitors was ...
DocWire News EditorsCardiology | September 14, 2023
Canagliflozin, recently approved for the reduction of heart attack and stroke risk in type 2 diabetics with known ...
DocWire News EditorsAHA Scientific Sessions 2018 | April 28, 2023
Subodh Verma, MD, of St. Michael's Hospital and University of Toronto, talks with DocWire News about the EMPA-HEART ...
DocWire News EditorsAHA Scientific Sessions 2018 | November 19, 2018
Stephen D. Wiviott, MD, talks with DocWire News, about the results and implications from the Dapagliflozin Effect on ...